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1 |  WHAT IS KNOWN AND 
OBJECTIVES
Peritoneal carcinomatosis arising from primary lung cancer 
is rare, and ileus due to peritoneal carcinomatosis is reported 
to be even more rare.1,2 Despite recent medical and surgical 
advances, the survival of patients suffering from this condi-
tion is extremely poor, and the median survival time from di-
agnosis is 1.3 months.1 The majority of patients receive only 
palliative care because of their low performance status (PS).3
Epidermal growth factor receptor (EGFR)-mutated lung 
cancer has a favorable prognosis, with a high response rate 
to EGFR-tyrosine kinase inhibitors (TKIs); consequently, 
EGFR-mutated lung cancer has a better overall survival 
time than other subtypes of lung cancer, despite the low PS 
of these patients.4 Therefore, patients with ileus due to peri-
toneal carcinomatosis may benefit from EGFR-TKIs. The 
purpose of this case report is to show the clinical efficacy 
and pharmacokinetics of osimertinib in peritoneal metastatic 
lung cancer patients with ileus.
Received: 18 October 2019 | Revised: 22 November 2019 | Accepted: 8 December 2019
DOI: 10.1002/ccr3.2645  
C A S E  R E P O R T
Clinical efficacy of osimertinib for a patient with ileus due to 
peritoneal carcinomatosis
Yo Kawaguchi1,2  |   Jun Hanaoka1 |   Hideki Hayashi3,4,5,6 |   Yoshihisa Fukuda4 |   
Hirotoshi Iihara3,6 |   Akio Suzuki6 |   Tadashi Sugiyama3,4,5
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
1Division of General Thoracic Surgery, 
Department of Surgery, Shiga University of 
Medical Science, Otsu City, Japan
2Division of General Thoracic Surgery, 
Kusatsu General Hospital, Kusatsu City, 
Japan
3Laboratory of Pharmacy Practice and 
Social Science, Gifu Pharmaceutical 
University, Gifu City, Japan
4Laboratory of Community Healthcare 
Pharmacy, Gifu Pharmaceutical University, 
Gifu City, Japan
5Laboratory of Home Team Care Pharmacy, 
Gifu Pharmaceutical University, Gifu City, 
Japan
6Department of Pharmacy, Gifu University 
Hospital, Gifu City, Japan
Correspondence
Yo Kawaguchi, Division of General 
Thoracic Surgery, Department of Surgery, 
Shiga University of Medical Science, 




We report a patient of stage IV lung adenocarcinoma who developed ileus due to 
peritoneal carcinomatosis. We placed an ileus tube and started an oral intake of osi-
mertinib. Within one month, the tumor had shrunk, and the ileus was controlled.
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2 |  CASE DESCRIPTION
A 42-year-old man presented to our hospital with abnormal 
shadows on a chest X-ray. He smoked 20 cigarettes per day 
for over 21  years. He had no history of diabetes, coronary 
artery disease, hypertension, hepatitis, drug allergies, or 
previous trauma but had previously undergone gastroduo-
denectomy for gastric and duodenal ulcers. Computed to-
mography revealed a round mass in the right upper lobe and 
right pleural effusion. A bronchoscopic examination was per-
formed, and the biopsy specimen showed adenocarcinoma. 
The patient was finally diagnosed with stage IV lung ade-
nocarcinoma (cT1aN0M1a) with an EGFR exon 19 deletion 
mutation. Twenty-four treatment cycles of first-line erlotinib 
150 mg and bevacizumab 15 mg/kg led to a partial response 
for 17  months before multiple lung metastases developed. 
Additionally, four treatment cycles of second-line carbo-
platin (AUC: 5) and pemetrexed (500 mg/m2) led to a par-
tial response for 4 months before multiple brain metastases 
developed, and the patient received a whole-brain radiation 
dose of 30 Gy. Three days after radiation treatment, abdomi-
nal distension, pain, and vomiting occurred. The abdominal 
X-ray showed gaseous distension of the bowel with air-fluid 
levels (Figure 1A), and the patient was diagnosed with ileus. 
Computed tomography showed ascites, dilatation, and col-
lapse of the small intestine and a partially thickened bowel 
wall (Figure 2), which suggested mechanical obstruction due 
to peritoneal carcinomatosis. The EGFR gene was analyzed 
by real-time polymerase chain reaction in cancer cells iso-
lated from the peritoneal fluid and revealed adenocarcinoma 
with a exon 19 deletion and Thr790Met mutation. We judged 
that there was no indication for a surgical procedure to treat 
the ileus because his PS decreased to 3. Therefore, we decided 
to treat the patient through nonsurgical procedures. First, we 
placed the end of the ileus tube near the obstruction site and 
drained fluid and gas from the bowel for 20 days, but the ileus 
was not controlled. The patient was subsequently initiated on 
oral osimertinib 80 mg PO daily on day 1. The osimertinib 
had administered by mouth during the treatment period. The 
ileus was controlled at day 16 as evidenced by a normal bowel 
movement and a decrease in bowel fluid from the ileus tube 
facilitated subsequent removal. An abdominal X-ray identi-
fied a decrease in bowel gas and the disappearance of air-fluid 
levels (Figure 1B). Moreover, multiple lung metastases mark-
edly reduced (Figure 3A,B). However, 4 months after starting 
osimertinib treatment, the patient died because of progression 
of the pleural carcinomatosis and multiple lung metastases.
Plasma samples were obtained after the administration of 
osimertinib at days 9, 16, and 23. The plasma concentrations 
of osimertinib were determined using liquid chromatogra-
phy/tandem mass spectrometry according to the previously 
reported method5 with minor modifications. The trough 
plasma concentrations of osimertinib on days 9, 16, and 23 
were 510, 921, and 835 nmol/L, respectively (Figure 4).
F I G U R E  1  A, Abdominal X-ray 
showing gaseous distension of the bowel 
with air-fluid levels. B Abdominal,X-
ray showing a decrease in bowel gas and 
disappearance of air-fluid levels
F I G U R E  2  Abdominal computed tomography showing the 
dilatation and collapse (arrow) of the small intestine and partial 
thickening of the bowel wall (arrow)
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Before we collected samples and performed analysis, 
we obtained written informed consent from the patient. 
Institutional review board approval was also obtained for this 
study (approval number: 2018-0704-05).
3 |  WHAT IS NEW AND 
CONCLUSION
Peritoneal carcinomatosis arising from primary lung cancer 
is rare and is predominantly seen as a manifestation of intra-
abdominal malignancy, such as colorectal or ovarian cancer. 
Among all cases of peritoneal carcinomatosis originating from 
extra-abdominal organs, 25.6% were lung cancer.1 Satoh et al 
reviewed the observations of 1041 lung cancer patients treated 
consecutively and found that 12 (1.2%) developed peritoneal in-
volvement over the course of the disease.2 Despite recent medi-
cal and surgical advances, the survival of these patients was 
extremely poor, and the median survival time from the diag-
nosis of peritoneal carcinomatosis was 1.3 months.1 Peritoneal 
carcinomatosis sometimes causes paralytic or obstructive ileus, 
lending to difficulties in treatment secondary to poor patient 
tolerability of appropriate treatment due to poor PS.
Not only surgery, but also several treatment options are 
now available for patients with ileus that are not surgical 
candidates. Nasogastric drainage is generally a temporary 
measure, and self-expanding metallic stents are an option 
for malignant obstructions. In terms of subsequent cancer 
therapy, conventional induction chemotherapy for these pa-
tients may be difficult because of their debilitated condition. 
Su et al reported that among 25 patients with peritoneal car-
cinomatosis in lung cancer, 16 patients could not receive 
chemotherapy due to their poor PS. Only nine patients could 
receive chemotherapy; however, their median survival time 
was 127 days.3 Patients without indications for conventional 
induction chemotherapy due to poor PS may benefit from 
EGFR-TKIs. When EGFR mutation-positive patients with 
PS of 3-4 received gefitinib, the disease control rate was 
90%, and 79% of the patients experienced improvements in 
their PS.4 Although oral intake is not a standard care for 
patients with ileus, there is likely clinical benefit of the 
oral administration of EGFR-TKIs secondary to disease 
progression.
The pharmacokinetics of osimertinib in patients with ileus 
is unknown. We need to identify the absorption mechanisms 
of the drug in these patients. We believe that for effective 
absorption, an environment for normal bowel fluid passage 
needs to be created in the small intestine. First, we placed 
the end of the ileus tube near the obstruction site and drained 
fluids and gas from the bowel. Second, the patient started 
to orally intake osimertinib. As a result, osimertinib was 
absorbed through the small bowel wall, the plasma concen-
tration of osimertinib was elevated, and the tumor markedly 
reduced. Tumor regression was followed by the resolution of 
the ileus. Kobayashi et al reported the effectiveness of afati-
nib in a lung cancer patient with ileus due to peritoneal car-
cinomatosis.6 The patient's ileus was also quickly controlled 
after afatinib treatment, which is similar to our results. A 
pharmacokinetic study on alvimopan, a mu opioid antagonist 
for postoperative ileus, demonstrated that the absorption and 
plasma levels of therapeutics might be higher than normal 
during ileus because of the longer residence time in the intes-
tine.7 In the same way as this report, the plasma concentration 
of osimertinib during ileus was higher than that from an in-
terview8 (Figure 4).
F I G U R E  3  A, Chest computed 
tomography showing multiple lung 
metastases and pleural effusion. B, Chest 
computed tomography showing that the lung 
metastases disappeared
F I G U R E  4  The trough plasma concentrations of osimertinib 
were 510 nmol/L (day 9), 921 nmol/L (day 16), and 835 nmol/L (day 
23). The trough plasma concentration of osimertinib reported from an 
interview was approximately 440 nmol/L (bar)
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This is the first report to demonstrate the plasma concentra-
tion and marked efficacy of osimertinib in a patient with ileus 
due to peritoneal carcinomatosis. In conclusion, we expect that 
EGFR mutation-positive lung cancer patients with ileus should 
receive EGFR-TKI therapy; additionally, to adequately absorb 
osimertinib into the plasma, the appropriate management of 
oral medication intake and an ileus tube is needed.
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